Αρχική World News A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed... World News A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma Από Ogkologos - 12 Ιανουαρίου, 2026 519 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... 11 Ιανουαρίου, 2024 Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among... 3 Σεπτεμβρίου, 2026 Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause... 4 Αυγούστου, 2026 Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays... 6 Μαΐου, 2021 Φόρτωση περισσοτέρων HOT NEWS Banking on breakthroughs for children and young people Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases